See more : Sumitomo Heavy Industries, Ltd. (6302.T) Income Statement Analysis – Financial Results
Complete financial analysis of SQZ Biotechnologies Company (SQZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SQZ Biotechnologies Company, a leading company in the Biotechnology industry within the Healthcare sector.
- Cactus Acquisition Corp. 1 Limited (CCTSU) Income Statement Analysis – Financial Results
- WebCash Corporation (053580.KQ) Income Statement Analysis – Financial Results
- China Tianying Inc. (000035.SZ) Income Statement Analysis – Financial Results
- Mongolia Energy Corporation Limited (MOAEY) Income Statement Analysis – Financial Results
- Daios Plastics S.A. (DAIOS.AT) Income Statement Analysis – Financial Results
SQZ Biotechnologies Company (SQZ)
About SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 21.03M | 27.10M | 21.00M | 19.32M | 12.67M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 21.03M | 27.10M | 21.00M | 19.32M | 12.67M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 70.98M | 70.15M | 51.55M | 36.10M | 24.38M |
| General & Administrative | 26.32M | 25.72M | 20.51M | 18.27M | 8.69M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.32M | 25.72M | 20.51M | 18.27M | 8.69M |
| Other Expenses | -449.00K | -8.00K | -13.00K | -791.00K | -1.13M |
| Operating Expenses | 96.85M | 95.87M | 72.06M | 53.58M | 31.94M |
| Cost & Expenses | 96.85M | 95.87M | 72.06M | 53.58M | 33.07M |
| Interest Income | 1.22M | 36.00K | 550.00K | 2.07M | 978.00K |
| Interest Expense | 9.72M | 0.00 | 0.00 | 0.00 | 59.00K |
| Depreciation & Amortization | 21.40M | 11.03M | 10.94M | 6.42M | 1.07M |
| EBITDA | -59.28M | -57.74M | -40.12M | -27.85M | -18.12M |
| EBITDA Ratio | -281.91% | -213.07% | -191.04% | -144.15% | -143.06% |
| Operating Income | -80.68M | -68.77M | -51.06M | -34.27M | -20.40M |
| Operating Income Ratio | -383.68% | -253.78% | -243.16% | -177.37% | -161.05% |
| Total Other Income/Expenses | 1.22M | 28.00K | 537.00K | 2.06M | 1.15M |
| Income Before Tax | -79.46M | -68.74M | -50.52M | -32.20M | -19.25M |
| Income Before Tax Ratio | -377.88% | -253.68% | -240.60% | -166.69% | -151.95% |
| Income Tax Expense | -1.22M | -36.00K | -550.00K | -7.00K | 1.21M |
| Net Income | -78.24M | -68.71M | -49.97M | -32.20M | -19.25M |
| Net Income Ratio | -372.08% | -253.54% | -237.98% | -166.66% | -151.95% |
| EPS | -2.72 | -2.49 | -9.25 | -1.80 | -1.34 |
| EPS Diluted | -2.72 | -2.49 | -9.25 | -1.80 | -1.34 |
| Weighted Avg Shares Out | 28.81M | 27.58M | 5.40M | 17.92M | 14.41M |
| Weighted Avg Shares Out (Dil) | 28.81M | 27.58M | 5.40M | 17.92M | 14.41M |
Serica Energy reports temporary production halt at Triton
Serica Energy reveals bumper volumes from Bittern well
Serica Energy calls UK oil and gas tax regime “unjustifiably punitive”
NYSE to Commence Delisting Proceedings Against SQZ Biotechnologies Company (SQZ)
SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates
SQZ Biotechnologies to Present at Upcoming Investor Conferences
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
SQZ Biotechnologies to Present at Jefferies Healthcare Conference
SQZ Biotechnologies to Present at Upcoming Investor Conferences
SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports